Lymphatic filariasis is an infectious tropical disease caused by parasitic round worms, i.e. Wuchereria bancrofti and Brugia malayi.
Lymphatic Filariasis Treatment: Introduction
- Lymphatic filariasis is an infectious tropical disease caused by parasitic round worms, i.e. Wuchereria bancrofti and Brugia malayi. Bancroftian lymphatic filariasis affects both the legs and the genitals. Brugia malayi affects the legs below the knees. This disease spreads through the bites of infected mosquitos. Mosquito-transmitted larvae are deposited on the skin, from where they can enter the body. The larvae then enter into the lymphatic vessels, where they develop into adult worms, thereby continuing a cycle of transmission.
- In the early stages of the infection, the patient shows symptoms such as fever, headaches, chills, and skin lesions. If the disease is left untreated, obstruction of the lymph flow will cause swelling in the legs and external genitals.
- Lymphatic filariasis is a common disease in the tropical regions of the world. The organism W. bancrofti is present across Asia, Africa, China, and South America. B. malayi is found in South and Southeast Asia. Lymphatic filariasis is extremely rare in North America and occurs only when these organisms are imported from tropical regions.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77632
Key Drivers of Global Lymphatic Filariasis Treatment Market
- Increase in incidence of lymphatic filariasis in tropical areas and rise in awareness programs by the WHO for the treatment of lymphatic filariasis are projected to boost the growth of the global lymphatic filariasis treatment market. According to the World Health Organization, in 2018, around 120 million people suffered from lymphatic filariasis and 40 million people were disfigured by the disease. The World Health Organization launched a global program to eliminate lymphatic filariasis in 2000. This program comprises two key strategies: mass drug administration to prevent infection and management of morbidity and prevention of disability.
- Major pharmaceutical companies focus on the design and development of new treatment options for this disease. For instance, AbbVie, Inc. has one innovative product, i.e. ABBV-4083, in pipeline (phase I) for treatment of lymphatic filariasis. Additionally, increase in government initiatives and rise in awareness about lymphatic filariasis among the general population fuel the growth of the global lymphatic filariasis treatment market. Moreover, rise in health care funding and improving health care facilities contribute to the growth of the global lymphatic filariasis treatment market.
- Late symptoms of the disease and less treatment options available are likely to restrain the lymphatic filariasis treatment market during the forecast period
Request for Analysis of COVID-19 Impact on Lymphatic Filariasis Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77632
Diethylcarbamazine Segment to Witness High Demand
- Based on drug type, the global lymphatic filariasis treatment market can be classified into diethylcarbamazine, doxycycline, and others
- The diethylcarbamazine segment accounted for the largest share of the global lymphatic filariasis treatment market in 2019. The segment is expected to dominate the global market due to increase in use of diethylcarbamazine in the treatment of lymphatic filariasis and focus of major manufacturers on the launch of new products containing diethylcarbamazine for treatment of lymphatic filariasis.
Hospital Pharmacies to be Most Promising Segment
- In terms of distribution channel, the global lymphatic filariasis treatment market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies was the largest segment in terms of revenue in 2019 and is anticipated to witness strong growth during the forecast period due to increase in number of patients with lymphatic filariasis who require hospital visit.
Pre book Lymphatic Filariasis Treatment Market Report at
https://www.transparencymarketresearch.com/checkout.php?rep_id=77632<ype=S
Asia Pacific to Dominate Global Lymphatic Filariasis Treatment Market
- In terms of region, the global lymphatic filariasis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific dominated the global lymphatic filariasis treatment market in 2019 and the trend is expected to continue during the forecast period. Large number of patients with lymphatic filariasis, early adoption of new products, and presence of major manufacturers are likely to fuel the growth of the lymphatic filariasis treatment market in Asia Pacific.
- The market in Middle East & Africa is projected to witness significant growth during the forecast period, owing to increase in new product launch and rise in demand for lymphatic filariasis treatment in emerging countries such as South Africa and others
Top of Form
Read More Information:
https://www.transparencymarketresearch.com/lymphatic-filariasis-treatment-market.html
Key Players Operating in Global Market
The global lymphatic filariasis treatment market was highly fragmented in 2019. Key players operating in the global market are:
- Abbott
- Anacor Pharmaceuticals, Inc.
- AbbVie, Inc.
- Eisai Co., Ltd.
- GlaxoSmithKline Pharmaceuticals Ltd.
- Wyeth Limited
- Cyper Pharma
- RND Laboratories Private Limited
- Other Prominent Players
Browse More Trending Reports by Transparency Market Research:
Multiplexed Diagnostics Market:
According to Transparency Market Research’s latest report on the global multiplexed diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in private and public funding for genomics and personalized medicine and growing demand for advanced diagnostic technology for accurate diagnosis of life-threatening diseases are projected to drive the global multiplexed diagnostics market during the forecast period
Neurological Disorder Drugs Market:
Brain injuries of various types and neurological diseases are one of the main causes of deaths worldwide. Hence, researchers are tapping into opportunities through glucose metabolism modification for the development of new drugs that could revolutionize the treatment of neurological disorders. For instance, Gero Discovery - a supplier of novel therapeutic options for neurodegenerative diseases, announced that they have found a potential drug that can help prevent neuronal deaths with the technique of glucose metabolism modification in stressed neurons. Thus, companies in the neurological disorder drugs market should collaborate with talented researchers to develop new drugs.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453